SI-BONE, Inc. (SIBN) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. SI-BONE, Inc. is a medical device company specializing in minimally invasive surgical implant systems for sacroiliac joint dysfunction and pelvic trauma. The company operates as a single reportable segment, with approximately 95% of revenue derived from the United States. As of March 31, 2025, the company had 42,479,600 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $47.3 million | $37.9 million |
| Gross Profit | $37.7 million | $29.9 million |
| Gross Margin | 80% | 79% |
| Net Loss | $(6.5) million | $(10.9) million |
| Diluted EPS | $(0.15) | $(0.27) |
| Cash & Marketable Securities | $144.4 million | $150.0 million (Dec 31, 2024) |
| Outstanding Debt (Principal) | $36.0 million | $36.0 million |
| Operating Cash Flow | $(4.9) million | $(7.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 25% year-over-year, driven primarily by a $9.4 million increase in U.S. revenue due to higher case volumes and an expanded product portfolio.
- Profitability Improvement: Net loss narrowed by 40% to $6.5 million. Operating loss decreased from $12.0 million to $7.5 million.
- Expense Management: Sales and marketing expenses rose 4% to $30.7 million, largely due to higher commissions tied to revenue growth. General and administrative expenses increased 22% to $10.0 million, driven by higher legal/consulting fees and headcount.
- Inventory Build: Inventory increased by $3.3 million to $30.4 million, reflecting strategic build-up for new product introductions.
- Debt Restructuring: In November 2024, the company refinanced its term loan (Third Amendment), extending the maturity to September 2029 and deferring the first principal payment to October 2027 (or 2028 upon achieving a performance milestone).
Outlook, Risks, and Contingencies
- Liquidity: Management believes existing cash and marketable securities ($144.4 million) are sufficient to fund operations for at least the next 12 months. The company has not yet achieved positive operating cash flow.
- Legal Investigation: In October 2024, the company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding the Anti-Kickback Statute and False Claims Act, focusing on meals and consulting payments to healthcare professionals. The company is cooperating but cannot estimate the financial impact or duration.
- Supply Chain Risks: The company faces risks related to titanium supply chains impacted by geopolitical events (Russia/Ukraine) and potential tariffs. Reliance on single-source suppliers for certain components and sterilization services poses operational risks.
- Regulatory Environment: Potential disruptions at the FDA due to government funding issues or workforce reductions could delay product approvals.
- Executive Compensation: On May 5, 2025, the Board approved enhanced severance benefits for the CEO in the event of a Change in Control, including 24 months of base salary and full equity acceleration.
Investor Verification Checklist
- Verify the status and potential financial exposure of the ongoing DOJ investigation regarding the Anti-Kickback Statute.
- Monitor the timeline for the first principal payment on the $36 million term loan (currently October 2027) and the conditions for the performance milestone that could defer this to 2028.
- Assess the impact of inventory build-up ($30.4 million) on future cash burn and the ability to convert this inventory into revenue as new products launch.
- Review the company's strategy for mitigating supply chain disruptions related to titanium sourcing and sterilization capacity.
- Track the results of the SILVIA and SAFFRON clinical trials, with primary endpoint results expected in the second half of 2025.